Circadian Technologies Releases Data From VGX-100 Trial
These data indicate that, if clinically validated, VGX-100 has the potential to be a useful new treatment for some types of cancer. VGX-100 is a fully human monoclonal
Evogene and ELEO have entered a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the Proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway for hyperlipidemia and cardiovascular diseases.